Skip to main content
. 2021 Jun 23;19:189. doi: 10.1186/s12951-021-00935-z

Fig. 8.

Fig. 8

Illustration of the formation of FeSiNTs/siSPAG5 nanomedicine and active targeting, and combinational RNAi therapy in bladder cancer. The FeSiNTs/siSPAG5 complex protects the SPAG5 siRNA from serum degradation by nucleases and clearance through the kidneys, and promotes SPAG5 siRNA accumulation in tumor cells, thereby silencing SPAG5 in bladder tumors. Downregulated SPAG5 expression inhibits bladder cancer growth and progression